Effect of 5-lipoxygenase blockade on blood pressure and acetylcholine-evoked endothelium-dependent contraction in aorta from spontaneously hypertensive rats

Journal of Hypertension

Volumn 24, Issue 1, 2006, Pages 85-93

  Lefebvre, Blandine ^a   Caron, Françoise ^a   Bessard, Germain ^a   Stanke Labesque, Françoise ^a  

^a University Grenoble Alpes   (France)

Author keywords

5 lipoxygenase; Acetylcholine; Cysteinyl leukotrienes; Endothelium; Hypertension; Nitric oxide inhibition; Rat aorta

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACETYLCHOLINE; ARACHIDONATE 5 LIPOXYGENASE; DOCEBENONE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; N(G) NITROARGININE; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN F2 ALPHA; VERLUKAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTERIAL PRESSURE; ARTICLE; BIOSYNTHESIS; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESSENTIAL HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RECEPTOR UPREGULATION; SPONTANEOUSLY HYPERTENSIVE RAT; STIMULATION; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

EID: 29144528197     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000198027.76729.b8     Document Type: Article

References (43)

1. Rouzer CA, Kargman S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J Biol Chem 1988; 263:10980-10988.
2. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343:282-284.
3. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett 2001; 487:323-326.
4. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, Nicosia S, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 2003; 55:195-227.
5. Porreca E, Di Febbo C, Di Sciullo A, Angelucci D, Nasuti M, Vitullo P, et al. Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost 1996; 76:99-104.
6. Stanke-Labesque F, Devillier P, Veitl S, Caron F, Cracowski JL, Bessard G. Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats. Cardiovasc Res 2001; 49:152-160.
7. Stanke-Labesque F, Hardy G, Vergnaud S, Devillier P, Peoc'h M, Randon J, et al. Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)27 rats. J Hypertens 2002; 20:263-272.
8. Stanke-Labesque F, Hardy G, Caron F, Cracowski JL, Bessard G. Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in I-NAME-treated rats. Br J Pharmacol 2003; 140:186-194.
9. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998; 97:2406-2413.
10. Folco G, Rossoni G, Buccellati C, Berti F, Maclouf J, Sala A. Leukotrienes in cardiovascular diseases. Am J Respir Crit Care Med 2000; 161:S112-S116.
11. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100:1238-1243.
12. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350:29-37.
13. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992; 85:230-236.
14. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233-239.
15. Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM, Boulanger CM. Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res 1995; 76:1003-1010.
16. Yang D, Feletou M, Boulanger CM, Wu HF, Levens N, Zhang JN, et al. Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol 2002; 136:104-110.
17. Yang D, Feletou M, Levens N, Zhang JN, Vanhoutte PM. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 2003; 41:143-148.
18. Jino H, Kurahashi K, Usui H, Nakata Y, Shimizu Y. Possible involvement of endothelial leukotrienes in acetylcholine-induced contraction in rabbit coronary artery. Life Sci 1996; 59:961-967.
19. Mazzetti L, Franchi-Micheli S, Nistri S, Quattrone S, Simone R, Ciuffi M, et al. The ACh-induced contraction in rat aortas is mediated by the Cys Lt1 receptor via intracellular calcium mobilization in smooth muscle cells. Br J Pharmacol 2003; 138:707-715.
20. Salas A, Panes J, Elizalde JI, Casadevall M, Anderson DC, Granger DN, et al. Mechanisms responsible for enhanced inflammatory response to ischemia-reperfusion in diabetes. Am J Physiol 1998; 275:H1773-H1781.
21. Raychaudhuri A, Chertock H, Peppard J, White WD, Koeler J, DiPasquale G. Effect of 5-lipoxygenase inhibitors on in situ LTB4 biosynthesis following calcium ionophore stimulation in the rat pleural cavity. Agents Actions 1993; 39:C43-C45.
22. Schini VB, Vanhoutte PM. Inhibitors of calmodulin impair the constitutive but not the inducible nitric oxide synthase activity in the rat aorta. J Pharmacol Exp Ther 1992; 261:553-559.
23. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Nitric oxide inactivates endothelium-derived contracting factor in the rat aorta. Hypertension 1992; 19:442-445.
24. Ito T, Kato T, Iwama Y, Muramatsu M, Shimizu K, Asano H, et al. Prostaglandin H2 as an endothelium-derived contracting factor and its interaction with endothelium-derived nitric oxide. J Hypertens 1991; 9:729-736.
25. Rouzer CA, Ford-Hutchinson AW, Morton HE, Gillard JW. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 1990; 265:1436-1442.
26. Yoshimoto T, Yokoyama C, Ochi K, Yamamoto S, Maki Y, Ashida Y, et al. 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim Biophys Acta 1982; 713:470-473.
27. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399:789-793.
28. Yang D, Levens N, Zhang JN, Vanhoutte PM, Feletou M. Specific potentiation of endothelium-dependent contractions in SHR by tetrahydrobiopterin. Hypertension 2003; 41:136-142.
29. Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase - a review. Prostaglandins Other Lipid Mediat 1998; 56:341-361.
30. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8:344-348.
31. Yang D, Gluais P, Zhang JN, Vanhoutte PM, Feletou M. Nitric oxide and inactivation of the endothelium-dependent contracting factor released by acetylcholine in spontaneously hypertensive rat. J Cardiovasc Pharmacol 2004; 43:815-820.
32. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Leveille C, Mancini JA, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343:278-281.
33. Steinhilber D. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr Med Chem 1999; 6:71-85.
34. Tong Z, Wu X, Kehrer JP. Increased expression of the lipocalin 24p3 as an apoptotic mechanism for MK886. Biochem J 2003; 372:203-210.
35. Gugliucci A, Ranzato L, Scorrano L, Colonna R, Petronilli V, Cusan C, et al. Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. J Biol Chem 2002; 277:31789-1795. E-pub 21 June 2002.
36. Walch L, Norel X, Gascard JP, Brink C. Functional studies of leukotriene receptors in vascular tissues. Am J Respir Crit Care Med 2000; 161:3107-3111.
37. Mong S, Wu HL, Clark MA, Gleason JG, Crooke ST. Leukotriene D4 receptor-mediated synthesis and release of arachidonic acid metabolites in guinea pig lung: induction of thromboxane and prostacyclin biosynthesis by leukotriene D4. J Pharmacol Exp Ther 1986; 239:63-70.
38. Franchi-Micheli S, Failli P, Mazzetti L, Bani D, Ciuffi M, Zilletti L. Mechanical stretch reveals different components of endothelial-mediated vascular tone in rat aortic strips. Br J Pharmacol 2000; 131:1355-1362.
39. Levick S, Brown L. Cardiavascular responses to leukotriene receptor antogonism. Cardiovasc J S Afr 2004; 15(Suppl. 1):S8-S9.
40. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 1990; 258:G527-G534.
41. Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002; 51:135-143.
42. Yasujima M, Abe K, Tanno M, Kohzuki M, Sato M, Omata K, et al. Role of the prostaglandin-thromboxane system in the development and maintenance of spontaneous hypertension in the rat. Agents Actions Suppl 1987; 22:133-138.
43. Iwama Y, Kato T, Muramatsu M, Asano H, Shimizu K, Toki Y, et al. Correlation with blood pressure of the acetylcholine-induced endothelium-derived contracting factor in the rat aorta. Hypertension 1992; 19:326-332.